Sign in
4

Changes in Ownership

Atea Pharmaceuticals, Inc. Filed Acc 0000899243-23-003600

Options or other derivatives

  • Chief Commercial Officer acquired 240,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Vavricka John Chief Commercial Officer 2023-01-31 Grant or award · Restricted Stock Units +100,000 100,000 D
Vavricka John Chief Commercial Officer 2023-01-31 Grant or award · Stock Option (Right to Buy) +140,000 140,000 D
Loading xslF345X03/doc4.xml…